Bayer

PRNewswire | January 17, 2017

Bayer today announced the appointment of Dr. Carsten Brunn as President of its Pharmaceuticals business in the Americas, comprising the United States, Canada, Central and Latin America. In this role, Dr. Brunn will report to Dieter Weinand, member of the Board of Management of Bayer AG and President of the Pharmaceutical division....

World Pharma News | February 14, 2017

Bayer AG and its cooperation partner Janssen Research & Development, LLC have announced that the Phase III trial COMPASS evaluating the efficacy and safety of rivaroxaban (Xarelto®) for the prevention of major adverse cardiac events (MACE) including cardiovascular death, myocardial infarction and stroke in patients with coronary artery disease (CAD) or peripheral artery disease (PAD) has met its primary endpoint ahead of time. Following a planned interim analysis conducted by the independent Dat...

Bayer | September 18, 2017

US regulators have issued an accelerated approval for Bayer’s relapsed follicular lymphoma therapy Aliqopa. The decision allows physicians in the country to prescribe the drug to patients who have received at least two prior systemic therapies. Follicular lymphoma is a slow-growing type of non-Hodgkin lymphoma, a cancer of the lymph system, and despite being the most common form of NHL is considered a rare disease with unmet need....

Pharmaphorum Media Limited | October 24, 2018

Bayer is planning regulatory filings of darolutamide in prostate cancer following phase III trial results showing it helped prevent the disease from spreading, in a niche where Pfizer and Johnson & Johnson have already gained a foothold. The German pharma developed darolutamide in partnership with Finland’s Orion Corporation, with the latter due to a series of payments when the drug is filed in major markets. The ARAMIS trial tested darolutamide in men with non-metastatic castra...